Title:
PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPH OF SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE DERIVATIVE AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/017365
Kind Code:
A1
Abstract:
The present application relates to a pharmaceutically acceptable salt and polymorph of a substituted pyrazolo[1,5-a]pyrimidin-7-amine derivative as represented by formula (I), a pharmaceutical composition comprising same, a preparation method therefor, and a use of the pharmaceutically acceptable salt and polymorph in the treatment or prevention of CDK9 activity-related diseases or CDK9 activity-mediated diseases.
Inventors:
DAN ZHAOLING (CN)
JIANG TAOTAO (CN)
WANG JIBIAO (CN)
XUE YUAN (CN)
JIANG TAOTAO (CN)
WANG JIBIAO (CN)
XUE YUAN (CN)
Application Number:
PCT/CN2023/108554
Publication Date:
January 25, 2024
Filing Date:
July 21, 2023
Export Citation:
Assignee:
SHANGHAI HAIYAN PHARMACEUTICAL TECH CO LTD (CN)
YANGTZE RIVER PHARM GROUP CO (CN)
YANGTZE RIVER PHARM GROUP CO (CN)
International Classes:
C07D487/04; A61K31/519; A61P35/00
Domestic Patent References:
| WO2022098843A1 | 2022-05-12 | |||
| WO2021216828A1 | 2021-10-28 | |||
| WO2022156779A1 | 2022-07-28 |
Foreign References:
| CN112996790A | 2021-06-18 | |||
| CN107427521A | 2017-12-01 |
Other References:
LIU, YI ET AL.: "Transcriptional Cyclin-dependent Kinases: Potential Drug Targets in Cancer Therapy", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 229, 16 December 2021 (2021-12-16), XP086930976, DOI: 10.1016/j.ejmech.2021.114056
Attorney, Agent or Firm:
ADVANCE CHINA IP LAW OFFICE (CN)
Download PDF: